Full results on Lilly's tirzepatide in obstructive sleep apnea

Eli Lilly (NYSE: LLY) has shared detailed results from the SURMOUNT-OSA Phase III trials evaluating tirzepatide injection (10 mg or 15 mg) for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, with and without positive airway pressure (PAP) therapy.

In both studies, tirzepatide achieved all primary and key secondary endpoints for both the efficacy and treatment-regimen estimands and demonstrated a mean reduction of up to 62.8% on the apnea-hypopnea index (AHI), or about 30 fewer events restricting or blocking a person's airflow per hour of sleep, compared to placebo. 

Full results were published in The New England Journal of Medicine (NEJM) and presented at the American Diabetes Association (ADA) 84th Scientific Sessions.